⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Sinecatechins ointment

پماد سینکاتچین (عصاره چای سبز)

⚠ Unverified

🧴 DermatologicalsTopical green-tea extract (anti-wart)

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Safety not established 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list 🇺🇸 FDA approved (NDA) NDA021902 ATC D06BB12

Market / country: 🇺🇸 USA

Veregen (US)

🧮 Dose calculator

Disease / regimen

Anogenital warts · Regimen source: FDA Veregen · 2.1 FDA Veregen · 2.2

⛔ About 0.5 cm strand per wart dabbed on with a finger, thin layer; three times daily until complete clearance, max 16 weeks. No need to wash off before the next dose. Not for eye, mouth, intravaginal or intra-anal use. FDA Veregen · 2.1 FDA Veregen · 2.2

🛡️ Safety & information

Warnings

• Not for urethral, intravaginal, cervical, rectal or intra-anal HPV disease; avoid open wounds; avoid sun/UV exposure of the treated area. FDA Veregen · 5

Formulations

Sinecatechins 15% ointment (30 g tube) — ointment 🇺🇸 USA FDA Veregen · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Veregen · 8.1
“Risk Summary There are no available data on Veregen use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Veregen · 8.2
“Risk Summary There are no data on the presence of sinecatechins in human or animal milk, the effects on the breastfed child, or the effects on milk production.”
👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Veregen · 8.4
“Safety and effectiveness in pediatric patients have not been established.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Veregen · 8.5
“Seven patients (1.4%), older than 65 years of age were treated with Veregen in clinical studies.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA021902
DailyMed (FDA label)FDA Veregen
MedlinePlus (NIH)❌ None
WHO ATC/DDDD06BB12
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Veregen · 3 FDA Veregen · 2.1 FDA Veregen · 2.2 FDA Veregen · 5 FDA Veregen · SPL approval / marketing category FDA Veregen · 8.1 FDA Veregen · 8.2 FDA Veregen · 8.4 FDA Veregen · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

HPV vaccine (9-valent)Imiquimod cream Podofilox gel